Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia

Leukemia Research

Volumn 33, Issue 4, 2009, Pages 511-517

  Lee, Sung Sook ^a   Lee, Je Hwan ^a   Lee, Jung Hee ^a   Kim, Dae Young ^a   Kim, Se Hyung ^a   Lim, Sung nam ^a   Lee, Young Shin ^a   Seol, Miee ^a   Ryu, Seong Gil ^a   Kang, Young Ah ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a   Chi, Hyun Sook ^a   Yun, Sung Cheol ^a   Lee, Kyoo Hyung ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

AML; Early relapse; Mitoxantrone; Refractory; Single dose

Indexed keywords

CYTARABINE; ETOPOSIDE; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SINGLE DRUG DOSE; SKIN TOXICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 60249083138     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.009     Document Type: Article

References (22)

1. Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Br J Haematol 104 (1999) 328-335
2. te Boekhorst P.A., Lowenberg B., van Kapel J., Nooter K., and Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9 (1995) 1025-1031
3. Henderson B.M., Dougherty W.J., James V.C., Tilley L.P., and Noble J.F. Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66 (1982) 1139-1143
4. Zbinden G., and Beilstein A.K. Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Toxicol Lett 11 (1982) 289-297
5. Heinemann V., Murray D., Walters R., Meyn R.E., and Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22 (1988) 205-210
6. Kano Y., Suzuki K., Akutsu M., and Suda K. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 6 (1992) 440-445
7. Thomas X., and Archimbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther 39 (1997) 63-74
8. Alberts D.S., Young L., Mason N., and Salmon S.E. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12 (1985) 38-42
9. Bhalla K., Ibrado A.M., Tourkina E., Tang C., Grant S., Bullock G., et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82 (1993) 3133-3140
10. Feldman E.J. Commentary: dose intensive chemotherapy in acute myeloid leukemia. Leuk Res 25 (2001) 217-219
11. Grant S., Arlin Z., Gewirtz D., and Feldman E. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 5 (1991) 336-339
12. Feldman E.J., Alberts D.S., Arlin Z., Ahmed T., Mittelman A., Baskind P., et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11 (1993) 2002-2009
13. Thomas X., Cambier N., Taksin A.L., Reman O., Vekhoff A., Pautas C., et al. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res 24 (2000) 957-963
14. Lee J.H., Choi S.J., Lee Y.S., Seol M., Ryu S.G., Jang S., et al. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leuk Res 30 (2006) 204-210
15. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003) 4642-4649
16. Thomas X., Elhamri M., Chelghoum Y., Reman O., Arnaud P., Raffoux E., et al. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial. Ann Hematol 84 (2005) 376-382
17. Bahng H., Lee J.H., Ahn J.H., Lee J.S., Kim S.H., Kim W.K., et al. Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. Leuk Res 25 (2001) 213-216
18. Lee J.H., Lee K.H., Kim S., Seol M., Kim S.H., Kim W.K., et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leuk Res 25 (2001) 305-312
19. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14 (2000) 476-479
20. Ferrara F., Palmieri S., and Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 89 (2004) 998-1008
21. Robak T., and Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 43 (2002) 281-291
22. Stanisic S., and Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2 (2002) 287-295